Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 1/2014

01.01.2014 | Esophagus (L Gerson, Section Editor)

Update on Ablation for Barrett’s Esophagus

verfasst von: Gary W. Falk

Erschienen in: Current Gastroenterology Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Endoscopic ablation has dramatically changed the treatment algorithm for patients with Barrett’s esophagus. Studies clearly show the benefits of this approach for patients with high-grade dysplasia and intramucosal carcinoma. Recent studies also provide evidence in support of this approach for patients with low-grade dysplasia but not for patients with nondysplastic Barrett’s epithelium. Endoscopic ablation is safe and efficacious in most but not all patients and disease progression may occur during initial therapy as well as after successful completion in a small difficult to identify subset of patients. Furthermore, the past year has provided us with a better understanding of the durability of endoscopic ablation with highly variable rates of disease recurrence. Studies are underway to help determine predictors of response and recurrence.
Literatur
1.
American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140:1084–91.CrossRefPubMed
2.
Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc. 2007;65:3–10.CrossRefPubMed
3.••
Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–46. This international consensus provides evidence-based recommendations for the management of patients with high-grade dysplasia and intramucosal adenocarcinoma.CrossRefPubMed
4.
Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.CrossRefPubMed
5.
Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–88.CrossRefPubMed
6.
Phoa KY, van Vilsteren FG, Pouw RE, Weusten BL, Schoon EJ, Bisschops R, et al. Radiofrequency Ablation in Barrett's Esophagus With Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). Gastroenterology. 2013;144:S-187.
7.
Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 2012;143:567–75.CrossRefPubMedCentralPubMed
8.
Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365:1375–83.CrossRefPubMed
9.
Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013;144:1375–83.CrossRefPubMed
10.
Fleischer DE, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781–9.CrossRefPubMed
11.
Falk GW. Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves. Dig Dis Sci. 2010;55:1811–4.CrossRefPubMed
12.
Manner H, Pech O, Heldmann Y, May A, Pohl J, Behrens A, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol. 2013;11:630–5.CrossRefPubMed
13.
Badreddine RJ, Prasad GA, Lewis JT, Lutzke LS, Borkenhagen LS, Dunagan KT, et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol. 2010;8:248–53.CrossRefPubMedCentralPubMed
14.
van Vilsteren FG, Phoa KN, Alvarez Herrero L, Pouw RE, Sondermeijer CM, van Lijnschoten I, et al. Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase. Clin Gastroenterol Hepatol. 2013;11:491–8.CrossRefPubMed
15.
van Vilsteren FG, Phoa KN, Alvarez Herrero L, Pouw RE, Sondermeijer CM, Visser M, et al. A simplified regimen for focal radiofrequency ablation of Barrett's mucosa: a randomized multicenter trial comparing two ablation regimens. Gastrointest Endosc. 2013;78:30–8.CrossRefPubMed
16.
Allen B, Kapoor N, Willert R, McEwan H, Fullarton G, Penman I. Endoscopic ablation of Barrett's neoplasia with a new focal radiofrequency device: initial experience with the Halo60. Endoscopy. 2012;44:707–10.CrossRefPubMed
17.••
Orman ES, Li N, Shaheen NJ. Efficacy and Durability of Radiofrequency Ablation for Barrett's Esophagus: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–55. This systemic review and meta-analysis provides well-done summary estimates of the initial efficacy of radiofrequency ablation, long-term durability, and complication rates, albeit with considerable study heterogeneity.CrossRefPubMed
18.••
Gupta M, Iyer PG, Lutzke L, Gorospe EC, Abrams JA, Falk GW, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86. This large multicenter consortium cohort study shows that compete eradication of intestinal metaplasia and dysplasia takes considerably longer than initially thought, and that recurrence of intestinal metaplasia occurs at a high rate.CrossRefPubMed
19.••
Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013;145:87–95. This large study of the British experience with radiofrequency ablation demonstrates a dysplasia clearance rate of 81 % at 1 year.CrossRefPubMed
20.
Shaheen NJ, Kim HP, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, et al. Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry. J Gastrointest Surg. 2013;17:21–8.CrossRefPubMed
21.
Hunt BM, Louie BE, Dunst CM, Lipham JC, Farivar AS, Sharata A, et al. Esophagectomy for failed endoscopic therapy in patients with high-grade dysplasia or intramucosal carcinoma. Dis Esophagus. 2013. doi:10.​1111/​dote.​12096.PubMed
22.
Dulai PS, Pohl H, Levenick JM, Gordon SR, MacKenzie TA, Rothstein RI. Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study. Gastrointest Endosc. 2013;77:534–41.CrossRefPubMed
23.
Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011;141:460–8.CrossRefPubMedCentralPubMed
24.
Orman ES, Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Spacek MB, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol. 2013;108:187–95.CrossRefPubMed
25.••
Phoa KN, Pouw RE, van Vilsteren FG, Sondermeijer CM, Ten Kate FJ, Visser M, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. 2013;145:96–104. Follow-up of 54 patients in the Netherlands demonstrates a sustained remission rate of high-grade dysplasia and intramucosal cancer of 90 % at 5 years.CrossRefPubMed
26.
Gosain S, Mercer K, Twaddell WS, Uradomo L, Greenwald BD. Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc. 2013;78:260–5.CrossRefPubMed
27.
Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol. 2006;101:1964–71.CrossRefPubMed
28.••
Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC. Defective barrier function in neosquamous epithelium. Am J Gastroenterol. 2013;108:386–91. Ex-vivo studies of neosquamous Barrett’s epithelium demonstrates dilated intracellular space and increased permeability when compared to native squamous epithelium.CrossRefPubMed
29.
Gupta N, Mathur SC, Dumot JA, Singh V, Gaddam S, Wani SB, et al. Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett's esophagus? Gastrointest Endosc. 2012;75:11–8.CrossRefPubMed
30.
Zhou C, Tsai TH, Lee HC, Kirtane T, Figueiredo M, Tao YK, et al. Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). Gastrointest Endosc. 2012;76:32–40.CrossRefPubMedCentralPubMed
31.
Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143:576–81.CrossRefPubMedCentralPubMed
32.
van Vilsteren FG, Alvarez Herrero L, Pouw RE, Schrijnders D, Sondermeijer CM, Bisschops R, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013;45:516–25.CrossRefPubMed
33.
Titi M, Overhiser A, Ulusarac O, Falk GW, Chak A, Wang K, et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology. 2012;143:564–6.CrossRefPubMed
34.
Konda VJ, Gonzalez Haba Ruiz M, Hart J, Waxman I. Development of subsquamous cancer after hybrid endoscopic therapy for intramucosal Barrett's cancer. Endoscopy. 2012;44 Suppl 2:E390-1.PubMed
35.
Lee JK, Cameron RG, Binmoeller KF, Shah JN, Shergill A, Garcia-Kennedy R, et al. Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrett's esophagus. Endoscopy. 2013;45:571–4.CrossRefPubMed
36.
Allende D, Dumot J, Yerian L. Esophageal squamous cell carcinoma arising after endoscopic ablation therapy of Barrett's esophagus with high-grade dysplasia. Report of a case. Dis Esophagus. 2013;26:314–8.CrossRefPubMed
37.
Gorospe EC, Gupta M, Prasad GA, Lewis JT, Wang KK. Double trouble: two cases of squamous carcinoma arising from Barrett's dysplasia after endoscopic mucosal resection. Am J Gastroenterol. 2012;107:1595–6.CrossRefPubMed
38.
Dua KS, Merrill J, Komorowski R. Neosquamous epithelium after ablation of Barrett's epithelium: cause for concern? Gastrointest Endosc. 2012;76:1082–3.CrossRefPubMed
Metadaten
Titel
Update on Ablation for Barrett’s Esophagus
verfasst von
Gary W. Falk
Publikationsdatum
01.01.2014
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 1/2014
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-013-0368-7

Weitere Artikel der Ausgabe 1/2014

Current Gastroenterology Reports 1/2014 Zur Ausgabe

Neuromuscular Disorders of the Gastrointestinal Tract (S Rao, Section Editor)

Interstitial Cells of Cajal: Update on Basic and Clinical Science

Liver (B Bacon, Section Editor)

Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery

Liver (B Bacon, Section Editor)

Advances in Alpha-1-Antitrypsin Deficiency Liver Disease

Esophagus (L Gerson, Section Editor)

Per-Oral Endoscopic Myotomy (POEM) for Esophageal Achalasia

Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)

Dietary Fructose Intolerance, Fructan Intolerance and FODMAPs

Liver (B Bacon, Section Editor)

Useful Tests for Hepatic Encephalopathy in Clinical Practice

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise